News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
736,330 Results
Type
Article (51987)
Company Profile (321)
Press Release (684022)
Section
Business (214299)
Career Advice (2840)
Deals (36877)
Drug Delivery (112)
Drug Development (85603)
Employer Resources (180)
FDA (16926)
Job Trends (15746)
News (363989)
Policy (35221)
Tag
Academia (2876)
Alliances (52177)
Alzheimer's disease (1343)
Approvals (16855)
Artificial intelligence (158)
Bankruptcy (376)
Best Places to Work (12109)
Biotechnology (227)
Breast cancer (198)
Cancer (1435)
Cardiovascular disease (121)
Career advice (2378)
CAR-T (102)
Cell therapy (306)
Clinical research (68244)
Collaboration (508)
Compensation (263)
COVID-19 (2739)
C-suite (120)
Data (1419)
Diabetes (183)
Diagnostics (6516)
Earnings (86517)
Employer resources (157)
Events (116065)
Executive appointments (409)
FDA (17620)
Funding (440)
Gene therapy (214)
GLP-1 (682)
Government (4761)
Healthcare (19913)
Infectious disease (2835)
Inflammatory bowel disease (121)
Interviews (550)
IPO (16742)
Job creations (4049)
Job search strategy (1969)
Layoffs (465)
Legal (8637)
Lung cancer (215)
Manufacturing (224)
Medical device (13816)
Medtech (13821)
Mergers & acquisitions (20277)
Metabolic disorders (498)
Neuroscience (1692)
NextGen Class of 2024 (7090)
Non-profit (4869)
Northern California (1724)
Obesity (283)
Opinion (228)
Patents (125)
People (60953)
Phase I (21181)
Phase II (29953)
Phase III (22390)
Pipeline (525)
Postmarket research (2908)
Preclinical (9069)
Radiopharmaceuticals (246)
Rare diseases (280)
Real estate (6347)
Regulatory (23355)
Research institute (2544)
Resumes & cover letters (452)
Southern California (1486)
Startups (3825)
United States (15596)
Vaccines (630)
Weight loss (215)
Date
Last 7 days (610)
Last 30 days (2415)
Last 365 days (36535)
2024 (36368)
2023 (41521)
2022 (52729)
2021 (57416)
2020 (56269)
2019 (49499)
2018 (37445)
2017 (34258)
2016 (34110)
2015 (40175)
2014 (34091)
2013 (29463)
2012 (31523)
2011 (32098)
2010 (30278)
Location
Africa (905)
Arizona (204)
Asia (41480)
Australia (7585)
California (3894)
Canada (1463)
China (312)
Colorado (176)
Connecticut (180)
Europe (91882)
Florida (542)
Georgia (138)
Illinois (415)
Indiana (233)
Maryland (656)
Massachusetts (3034)
Michigan (178)
Minnesota (304)
New Jersey (1125)
New York (1097)
North Carolina (806)
Northern California (1724)
Ohio (149)
Pennsylvania (935)
South America (1284)
Southern California (1486)
Texas (556)
Utah (111)
Washington State (411)
736,330 Results for "kaleo formerly known as intelliject inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
Baxter International Inc. announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis.
May 29, 2024
·
5 min read
Press Releases
StimCell Energetics Inc. (Formerly “Cell MedX Corp.”) Announces Major Corporate Updates and Rebranding
November 4, 2024
·
3 min read
Kaleo Pharma
Drug Development
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
89bio, Inc. today announced the initiation of its Phase 3 ENLIGHTEN Program evaluating the efficacy and safety of pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH).
March 12, 2024
·
8 min read
Biotech Beach
Allez Health Announces $60 Million Capital Raise
Allez Health Inc., formerly known as Zense-Life Inc., an emerging biosensor venture founded by proven experts in the continuous glucose monitoring space, announced a $60 million Series A+ financing.
May 22, 2024
·
2 min read
Spur Therapeutics (Formerly Freeline) Announces New Name and Brand
Spur Therapeutics, formerly Freeline Therapeutics, today announced a new name and brand to reflect its focus on developing a new generation of gene therapies and advancing the practice of genetic medicine.
June 17, 2024
·
5 min read
Press Releases
Parabilis Medicines™ – Formerly FogPharma – Announces New Company Name and Unveils AI- and Physics-Based Discovery Platform
October 28, 2024
·
3 min read
Drug Development
AltruBio Raises $225M in Series B to Advance Ulcerative Colitis Candidate
Formerly known as AbGenomics Holding, AltruBio on Tuesday said it will use the funds to push its ulcerative colitis asset into a Phase IIb trial with an anticipated readout in 2026.
May 21, 2024
·
2 min read
·
Tyler Patchen
Press Releases
New SELECT trial analysis with semaglutide 2.4 mg showed a significant reduction in hospital admissions in adults with known heart disease and obesity or overweight
November 4, 2024
·
6 min read
Drug Development
Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk
Ventus Therapeutics, Inc. today announced that its partner, Novo Nordisk, has successfully dosed the first participant in a Phase 1 clinical study for NNC6022-0001 (formerly known as VENT-01).
May 3, 2024
·
6 min read
1 of 73,633
Next
